Oncocyte Announces Additional Favorable Data Regarding Its Lead Assay VitaGraft, Which Was Published In The Journal, Nephrology Dialysis Transplantation
Oncocyte Announces Additional Favorable Data Regarding Its Lead Assay VitaGraft, Which Was Published In The Journal, Nephrology Dialysis Transplantation
Oncocyte宣佈關於其首要檢驗VitaGraft的更多積極數據，相關內容已發表在《腎臟病透析移植》期刊上。
- Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population
- Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies
- Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection.
- Study published in Nephrology Dialysis Transplantation
- Oncocyte 首先發布了隨機干預數據，以確定在高風險患者群體中進行活檢的必要性。
- 研究表明，使用 Oncocyte 的檢測顯著縮短了新發展出供體特異性抗體患者的拒絕診斷時間。
- 隨着新型治療方法在抗體介導的排斥反應中顯示出有希望的早期效果，早期發現移植排斥反應的重要性日益增長。
- 研究發佈在《腎臟病透析移植》期刊上。
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft, which was published in the journal, Nephrology Dialysis Transplantation.
加利福尼亞州爾灣，2024年12月02日（GLOBE NEWSWIRE）-- Oncocyte corp.（納斯達克：OCX），一家診斷科技公司，今天宣佈了關於其主要檢測VitaGraft的更多有利數據，該數據已發表在《腎臟病透析移植》期刊上。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。